Evofem Biosciences, Inc. (EVFM) News

Evofem Biosciences, Inc. (EVFM): $0.91

-0.22 (-19.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVFM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter EVFM News Items

EVFM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EVFM News Highlights

  • For EVFM, its 30 day story count is now at 3.
  • Over the past 9 days, the trend for EVFM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about EVFM are DRUG.

Latest EVFM News From Around the Web

Below are the latest news stories about Evofem Biosciences Inc that investors may wish to consider to help them evaluate EVFM as an investment opportunity.

Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m. PT).

Yahoo | February 17, 2022

FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious Disease Product" (QIDP) Designation to EVO100 (the investigational name for Phexxi® (lactic acid, citric acid and potassium bitartrate)) for the prevention of urogenital chlamydia infection in women, a potential new indication in late stage clinical development. Chlamydia is the most frequently reported bacterial infection in the United States.

Yahoo | February 9, 2022

Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022

Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows:

Yahoo | February 8, 2022

Callan Capital, LLC Buys Schwab Fundamental U.S. ...

La Jolla, CA, based Investment company Callan Capital, LLC (Current Portfolio) buys Schwab Fundamental U.S.

Yahoo | January 21, 2022

Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).

Yahoo | January 19, 2022

EVFM Stock Heats Up Following ''Huge Win.'' 7 Things to Know.

Today, investors in women''s health company Evofem Biosciences and EVFM stock are dancing, following revised birth control regulations.

InvestorPlace | January 12, 2022

Evofem scores a “huge win” with revised birth control guidelines - Stifel

Evofem Biosciences <> has gained over a tenth after the company highlighted the impact on its birth control gel Phexxi post new federal guidance requiring the payors to…

Seeking Alpha | January 12, 2022

Evofem gains amid prospects for its contraceptive gel under new govt. guidance

Micro-cap stock Evofem Biosciences (EVFM) has gained ~30.0% on above-average volume after the company highlighted how a newly issued guidance from the U.S

Seeking Alpha | January 12, 2022

Why Are Evofem Biosciences Shares Rising On Wednesday?

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading higher after the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor issued updated guidance related to contraceptive access. The new guidance specifies that most insurers and pharmacy benefit managers (PBMs) must provide coverage, with no out-of-pocket costs to women, for FDA-approved contraceptive products, like Phexxi, prescribed by healthcare providers. "We believe this is a huge step forward toward ens

Yahoo | January 12, 2022

Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women

Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access.

Yahoo | January 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5281 seconds.